KRS Global Biotechnology 503B State-of-the-Art Facility

KRS Global Biotechnology 503B State-of-the-Art Facility

KRS Global Biotechnology is a 503B Facility supporting Hospitals, ASC's and VA Medical Centers nationwide. It is UNDER NEW OWNERSHIP AND MANAGEMENT since 2019, and is an FDA and DEA registered 503B Human Outsourcing Facility that provides sterile intravenous compounded products to hospitals, surgery centers, medical clinics, and medical institutions nationwide. The company operates in the Biotechnology and Pharmaceutical industries.

Founded in 2019, KRS Global Biotechnology has positioned itself as a pivotal player in the healthcare industry, focusing on the production and distribution of critical medical products.

With its state-of-the-art facility, KRS Global Biotechnology boasts a promising future and potential for growth in the healthcare market. As of now, no specific headquarters location has been publicly disclosed.

Considering the information available, there is no record of the company's last_investment or last_investment_investors.

In summary, KRS Global Biotechnology has established itself as a critical player in the healthcare industry within a short period. Its growth and potential for further advances make it an intriguing prospect for potential investors seeking opportunities in the biotechnology and pharmaceutical sectors.